Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study.

Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, Hussain A, Modiano M, Singh P, Tagawa ST, Gore I, McClay EF, Mega AE, Sartor AO, Somer B, Wadlow R, Shore ND, Olson WC, Stambler N, DiPippo VA, Israel RJ.

Prostate. 2019 Nov 19. doi: 10.1002/pros.23922. [Epub ahead of print]

PMID:
31742767
2.

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use.

Appukkuttan S, Tangirala K, Babajanyan S, Wen L, Simmons S, Shore N.

Pharmacoecon Open. 2019 Oct 22. doi: 10.1007/s41669-019-00185-8. [Epub ahead of print]

3.

The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data.

Crawford ED, Twardowski PW, Concepcion RS, Hafron JM, Harris RG, Moul JW, Gordan LN, Petrylak DP, Atkinson S, Boldt-Houle D, Keane TE, Higano CS, Henderson RJ, Kader AK, Hussain MH, Shore ND.

J Urol. 2019 Oct 3:101097JU0000000000000577. doi: 10.1097/JU.0000000000000577. [Epub ahead of print]

PMID:
31580749
4.

Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.

Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, Ploeger B, Moss J, Prien O, Borghesi G, Petrenciuc O, Tammela TL, Kuss I, Verholen F, Smith MR, Fizazi K.

Target Oncol. 2019 Oct;14(5):527-539. doi: 10.1007/s11523-019-00674-0.

5.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.

PMID:
31483485
6.

Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAAcT).

Shore ND, Saltzstein D, Sieber P, Mehlhaff B, Gervasi L, Phillips J, Wong YN, Pei H, McGowan T.

Clin Genitourin Cancer. 2019 Aug 6. pii: S1558-7673(19)30245-9. doi: 10.1016/j.clgc.2019.07.017. [Epub ahead of print]

PMID:
31473120
7.

Advances in Targeted Alpha Therapy for Prostate Cancer.

De Vincentis G, Gerritsen W, Gschwend JE, Hacker M, Lewington V, O'Sullivan JM, Oya M, Pacilio M, Parker C, Shore N, Sartor O.

Ann Oncol. 2019 Aug 16. pii: mdz270. doi: 10.1093/annonc/mdz270. [Epub ahead of print]

PMID:
31418764
8.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.

J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22.

PMID:
31329516
9.

AUTHOR REPLY.

Shelton JB, Shore N.

Urology. 2019 Jul;129:86. doi: 10.1016/j.urology.2019.01.063. No abstract available.

PMID:
31235007
10.

Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review.

Williams SB, Ray-Zack MD, Hudgins HK, Oldenburg J, Trinh QD, Nguyen PL, Shore ND, Wirth MP, O'Brien T, Catto JWF.

Eur Urol Oncol. 2019 May;2(3):265-273. doi: 10.1016/j.euo.2018.10.006. Epub 2018 Nov 5. Review.

PMID:
31200840
11.

Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy.

Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y.

Eur Urol. 2019 Aug;76(2):238-243. doi: 10.1016/j.eururo.2019.04.035. Epub 2019 May 16.

12.

Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.

Meng MV, Gschwend JE, Shore N, Grossfeld GD, Mostafid H, Black PC.

J Urol. 2019 Dec;202(6):1111-1119. doi: 10.1097/JU.0000000000000297. Epub 2019 May 1. Review.

PMID:
31042108
13.

Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States.

Shelton JB, Paivanas TA, Buffington P, Ruyle SR, Cohen ES, Natale R 2nd, Mehlhaff B, Suh R, Bradford TJ, Koo AS, Kwan L, Shore N.

Urology. 2019 Aug;130:72-78. doi: 10.1016/j.urology.2019.04.017. Epub 2019 Apr 25.

PMID:
31029668
14.

Prolonged PSA stabilization and overall survival following sipuleucel-T monotherapy in metastatic castration-resistant prostate cancer patients.

Holl EK, McNamara MA, Healy P, Anand M, Concepcion RS, Breland CD, Dumbudze I, Tutrone R, Shore N, Armstrong AJ, Harrison M, Wallace JA, Wu Y, George DJ.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):588-592. doi: 10.1038/s41391-019-0144-3. Epub 2019 Apr 12.

PMID:
30980027
15.

Contemporary Management of Incident Prostate Cancer in Large Community Urology Practices in the United States.

Shelton JB, Buffington P, Augspurger R, Gaylis F, Cohen T, Mehlhaff B, Suh R, Bradford TJ, Kwan L, Koo AS, Shore N.

Urology. 2019 Jul;129:79-86. doi: 10.1016/j.urology.2019.01.061. Epub 2019 Apr 5.

PMID:
30954610
16.

A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients.

Shore N, Mincik I, DeGuenther M, Student V Jr, Jievaltas M, Patockova J, Simpson K, Hu CH, Huang ST, Li Y, Lee Y, Chien B, Mao J.

World J Urol. 2019 Apr 3. doi: 10.1007/s00345-019-02741-7. [Epub ahead of print]

PMID:
30941562
17.

A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.

Shore ND, Guerrero S, Sanahuja RM, Gambús G, Parente A.

Clin Ther. 2019 Mar;41(3):412-425. doi: 10.1016/j.clinthera.2019.01.004. Epub 2019 Feb 8.

PMID:
30929678
18.

Emerging therapeutic targets for patients with advanced prostate cancer.

Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA.

Cancer Treat Rev. 2019 Jun;76:1-9. doi: 10.1016/j.ctrv.2019.03.002. Epub 2019 Mar 19. Review.

PMID:
30913454
19.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
20.

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators.

N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.

PMID:
30763142
21.

Efficacy and safety of fexapotide triflutate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia.

Shore N, Tutrone R, Roehrborn CG.

Ther Adv Urol. 2019 Jan 14;11:1756287218820807. doi: 10.1177/1756287218820807. eCollection 2019 Jan-Dec. Review.

22.

Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.

Petrylak DP, Kantoff P, Vogelzang NJ, Mega A, Fleming MT, Stephenson JJ Jr, Frank R, Shore ND, Dreicer R, McClay EF, Berry WR, Agarwal M, DiPippo VA, Rotshteyn Y, Stambler N, Olson WC, Morris SA, Israel RJ.

Prostate. 2019 May;79(6):604-613. doi: 10.1002/pros.23765. Epub 2019 Jan 20.

PMID:
30663074
23.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist.

Crawford ED, Tombal B, Keane T, Boccardo F, Miller K, Shore N, Moul JW, Damber JE, Collette L, Persson BE.

Scand J Urol. 2018 Oct - Dec;52(5-6):349-357. doi: 10.1080/21681805.2018.1522372. Epub 2019 Jan 9.

PMID:
30624128
24.

LUGPA Celebrates Its 10th Anniversary at Its 2018 Annual Meeting.

Shore ND.

Rev Urol. 2018;20(3):131-132. doi: 10.3909/riu0816. No abstract available.

25.

Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.

Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lindén O, Noordzij W, Park J, Saad F.

JAMA Oncol. 2018 Dec 1;4(12):1765-1772. doi: 10.1001/jamaoncol.2018.4044. Review.

PMID:
30326033
26.

Member Census Shows LUGPA Practices Exhibit High Level of Innovation, Sophistication, and Growth.

Sellinger SB, Shore ND.

Rev Urol. 2018;20(2):94-97. doi: 10.3909/riu0805. No abstract available.

27.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

28.

A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.

McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P.

Eur Urol. 2018 Dec;74(6):731-738. doi: 10.1016/j.eururo.2018.08.019. Epub 2018 Sep 17.

29.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

30.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

32.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; RADAR III Group.

J Urol. 2019 Apr;201(4):682-692. doi: 10.1016/j.juro.2018.05.164. Review.

PMID:
30077557
33.

Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.

Gupta S, Nordquist LT, Fleming MT, Berry WR, Zhang J, Ervin SL, Eisner JR, Baskin-Bey ES, Shore ND.

Clin Cancer Res. 2018 Nov 1;24(21):5225-5232. doi: 10.1158/1078-0432.CCR-18-0564. Epub 2018 Jul 16.

34.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

35.
36.

Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.

Levin RA, Lund ME, Truong Q, Wu A, Shore ND, Saltzstein DR, Concepcion RS, Paivanas TA, van Breda A, Beebe-Dimmer J, Ruterbusch JJ, Wissmueller S, Campbell DH, Walsh BJ.

Oncotarget. 2018 Apr 27;9(32):22359-22367. doi: 10.18632/oncotarget.25009. eCollection 2018 Apr 27.

37.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.

J Urol. 2018 Nov;200(5):956-966. doi: 10.1016/j.juro.2018.04.083. Epub 2018 May 3. Review.

PMID:
29730201
38.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan CJ, Crawford ED, Shore ND, Underwood W 3rd, Taplin ME, Londhe A, Francis PSJ, Phillips J, McGowan T, Kantoff PW.

J Urol. 2018 Aug;200(2):344-352. doi: 10.1016/j.juro.2018.03.125. Epub 2018 Apr 6.

39.

Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective.

Sade JP, Báez CAV, Greco M, Martínez CH, Avitia MÁÁ, Palazzo C, Toriz NH, Trujillo PIB, Bastos DA, Schutz FA, Bella S, Nogueira L, Shore ND.

Med Oncol. 2018 Mar 19;35(4):56. doi: 10.1007/s12032-018-1105-8. Review.

40.

Are You Developing an ABC: Advanced Bladder Cancer Clinic?

Shore ND.

Rev Urol. 2017;19(4):246-247. doi: 10.3909/riu0777. Review. No abstract available.

41.

Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.

Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A, Crawford ED.

Ther Adv Urol. 2017 Nov 22;10(2):43-50. doi: 10.1177/1756287217738150. eCollection 2018 Feb.

42.

Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.

Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF.

Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8.

43.

Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement.

Shore N, Tutrone R, Efros M, Bidair M, Wachs B, Kalota S, Freedman S, Bailen J, Levin R, Richardson S, Kaminetsky J, Snyder J, Shepard B, Goldberg K, Hay A, Gange S, Grunberger I.

World J Urol. 2018 May;36(5):801-809. doi: 10.1007/s00345-018-2185-y. Epub 2018 Jan 29.

44.

Prostatectomy-based validation of combined urine and plasma test for predicting high grade prostate cancer.

Albitar M, Ma W, Lund L, Shahbaba B, Uchio E, Feddersen S, Moylan D, Wojno K, Shore N.

Prostate. 2018 Mar;78(4):294-299. doi: 10.1002/pros.23473. Epub 2018 Jan 8.

PMID:
29315679
45.

Alternative payment models.

Kapoor DA, Shore ND.

Rev Urol. 2017;19(3):198-199. doi: 10.3909/riu193NewsinUro. No abstract available.

46.

Practice management for urology groups: LUGPA's Guidebook.

Shore ND.

Rev Urol. 2017;19(3):164-168. doi: 10.3909/riu0774. No abstract available.

47.

Current approaches to incorporation of radium-223 in clinical practice.

Parker C, Heidenreich A, Nilsson S, Shore N.

Prostate Cancer Prostatic Dis. 2018 Apr;21(1):37-47. doi: 10.1038/s41391-017-0020-y. Epub 2018 Jan 3. Review.

48.

Relationship between patient-reported outcomes and clinical outcomes in metastatic castration-resistant prostate cancer: post hoc analysis of COU-AA-301 and COU-AA-302.

Cella D, Traina S, Li T, Johnson K, Ho KF, Molina A, Shore ND.

Ann Oncol. 2018 Feb 1;29(2):392-397. doi: 10.1093/annonc/mdx759.

PMID:
29237083
49.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

50.

eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer.

Shore ND, Tutrone RF, Mariados NF, Nordquist LT, Mehlhaff BA, Steere KJ, Harrelson SS.

Clin Genitourin Cancer. 2018 Apr;16(2):149-154. doi: 10.1016/j.clgc.2017.10.022. Epub 2017 Nov 7.

Supplemental Content

Support Center